Drug Profile
Epinastine ophthalmic - AbbVie
Alternative Names: Alesion LX Ophthalmic Solution; Alesion Ophthalmic Solution; DE-114; DE-114A; Elestat; Epinastine eye drops; Epinastine hydrochloride; Epinastine hydrochloride high dose; Purivist; Relestat; STN-1011402Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Developer AbbVie; Santen Pharmaceutical
- Class Antiallergics; Dibenzazepines; Eye disorder therapies; Imidazoles; Nonsedating antihistamines; Small molecules
- Mechanism of Action Histamine H1 receptor antagonists; Histamine H2 receptor antagonists; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Allergic conjunctivitis
Most Recent Events
- 31 Mar 2023 Preregistration for Allergic conjunctivitis in Japan (Ophthalmic) (Santen Pharmaceutical pipeline, July 2023)
- 31 Oct 2022 Santen Pharmaceutical completes a phase-III clinical trial in Allergic conjunctivitis in Japan in October 2022 (Ophthalmic) (Santen Pharmaceutical pipeline, November 2022)
- 08 May 2020 Allergan has been acquired and merged into AbbVie